EVONILE · Biotechnology & Drugs
Evonile Pharma Ltd (EVONILE) share price, volume, delivery and quarterly results
As of 12 Nov close
Evonile Pharma Ltd (EVONILE) is listed on the NSE and grouped under Biotechnology & Drugs. Its latest reported quarter ended 30 Jun 2026.
Fundamentals: 30 Jun 2026 quarter, fetched 15 Sept; 8 of 8 figures available. What “not available” means
52-week range
As of 12 Nov 2026 close
The 52-week range is not shown because a corporate action makes the price history not comparable.
Delivery and volume
As of 12 Nov 2026 close
Delivery % over the last 20 sessions
| Session | Delivery % |
|---|---|
| 12 Nov 2026 | 41.1% |
| 11 Nov 2026 | 56.2% |
| 09 Nov 2026 | 71.5% |
| 06 Nov 2026 | 76.8% |
| 05 Nov 2026 | 65.3% |
Volatility (past price movement)
As of 12 Nov 2026 close
Among the most volatile 10% of stocks Rank 73 of 2115 ranked stocks (1 is the most volatile).
Based on the 21 daily moves up to the date shown. Past price movement, not a forecast.
Quarterly results
Latest quarter ended 30 Jun 2026. Figures in ₹ crore as reported.
| Quarter ended | Revenue | Net profit | Margin % | EPS ₹ |
|---|---|---|---|---|
| 30 Jun 2026 | 104 | 32 | 33.2% | 13.05 |
| 31 Mar 2026 | 91 | 25 | 22.3% | 10.23 |
| 31 Dec 2025 | 86 | 16 | 25.5% | 6.52 |
| 30 Sep 2025 | 90 | 24 | 25.9% | 9.81 |
| 30 Jun 2025 | 88 | 28 | 30.5% | 11.19 |
| 31 Mar 2025 | 84 | 29 | 27.9% | 11.87 |
| 31 Dec 2024 | 93 | 25 | 26.9% | 10.31 |
| 30 Sep 2024 | 87 | 20 | 19.9% | 8.27 |
P/E (trailing 12 months)
36.21
Results to 30 Jun 2026
Return on equity
11.9%
Results to 30 Jun 2026
Price to book
6.64
Results to 30 Jun 2026
Debt to equity
0
Results to 30 Jun 2026
Shareholding on 29 Jul 2026: promoters 70.7%, foreign institutions 0.1%, mutual funds 0.7%.
Insider trade disclosures
Filed disclosures, shown by trade date. Category of the person and mode as filed; names are not shown.
No insider trade disclosures are stored for this stock.
Bulk and block deals
Daily totals across the deals reported for the stock.
No bulk or block deals are stored for this stock.
Concall summaries
Summaries of the earnings transcripts the company has filed, with the source filing.
No concall summary is stored for this stock.
Latest news
No related news.